1  of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no e

2 , -0.1 to 1.2 kg) when receiving 50 mg/wk of testosterone enanthate, 2.6 kg (95% CI, 0.9 to 4.3 kg) f

3 ne, all men received (in addition to Lupron) testosterone enanthate (200 mg intramuscular) or placebo

4 al design, patients were assigned to receive testosterone enanthate (200 mg/wk) or placebo injections

5                                              Testosterone enanthate, 200 mg/wk (intramuscularly), for

6 , -0.1 to 1.7 kg) when receiving 50 mg/wk of testosterone enanthate, 3.5 kg (95% CI, 2.1 to 4.8 kg) f

7   Patients were randomly assigned to receive testosterone enanthate, 300 mg, or placebo intramuscular

8 ast 10 days of each 28-day cycle [HRT]; men: testosterone enanthate, biweekly intramuscular injection

9 roups received 50, 125, 300, or 600 mg/wk of testosterone enanthate for 20 weeks plus placebo (4 grou

10 testosterone enthanate with dutasteride plus testosterone enanthate from May 2005 through June 2010.

11 s of testosterone supplementation (100 mg of testosterone enanthate injected weekly) with or without

12 potheses in healthy young males by injecting testosterone enanthate or a placebo in a double-blind, b

13  were randomly assigned to receive 150 mg of testosterone enanthate or matching placebo intramuscular

14     The men received injections of 600 mg of testosterone enanthate or placebo weekly for 10 weeks.

15 tein breakdown decreased almost 2-fold after testosterone enanthate (p <.05), resulting in an improve

16 onadectomy (GX), or GX plus supraphysiologic testosterone-enanthate (TE) administration.